<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>Inbox Robot: Intestinal Cancer News</title>
<link>http://www.inboxrobot.com/news/intestinal-cancer</link><description>Constantly updated news and information about a variety of topics.</description><item>
<title>33rd ESMO Congress in Stockholm, 12-16 September 2008</title>
<link>http://www.inboxrobot.com/news.php?fid=186676848</link>
<pubDate>5 Sep 2008 15:37 GMT</pubDate>
<description>
...  benefits in terms of survival, new results show presented by Spanish researcher Emilio Alba. Gastrointestinal cancer Late breaking data: New drug substantially extends survival in pancreatic cancer (Embargoed until Tuesday,  ...
</description>
</item><item>
<title>Schering Plough, Merck: Potential Cancer Concerns</title>
<link>http://www.inboxrobot.com/news.php?fid=186333551</link>
<pubDate>3 Sep 2008 16:53 GMT</pubDate>
<description>
...  IMPROVE-IT findings because SGP and MRK provided funding for the SHARP and IMPROVE-IT studies Gastrointestinal cancers appeared higher in the Vytorin group: Stomach cancers were 5 vs. 1 in the  ...
</description>
</item><item>
<title>Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer</title>
<link>http://www.inboxrobot.com/news.php?fid=186084028</link>
<pubDate>2 Sep 2008 11:29 GMT</pubDate>
<description>
...  in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal  ...
</description>
</item></channel>
</rss>
